Medexus Pharmaceuticals Inc. (TSE:MDP - Free Report) - Equities researchers at Raymond James Financial lowered their Q4 2026 earnings per share (EPS) estimates for shares of Medexus Pharmaceuticals in a research note issued on Thursday, June 26th. Raymond James Financial analyst M. Freeman now anticipates that the company will post earnings per share of $0.01 for the quarter, down from their previous forecast of $0.06. The consensus estimate for Medexus Pharmaceuticals' current full-year earnings is $0.16 per share. Raymond James Financial also issued estimates for Medexus Pharmaceuticals' FY2030 earnings at $2.60 EPS.
Medexus Pharmaceuticals Price Performance
Shares of MDP stock opened at C$3.15 on Monday. The business's fifty day moving average price is C$2.85 and its 200 day moving average price is C$3.00. Medexus Pharmaceuticals has a 1-year low of C$1.71 and a 1-year high of C$5.56. The firm has a market capitalization of C$70.52 million, a PE ratio of 15.06 and a beta of 1.96.
About Medexus Pharmaceuticals
(
Get Free Report)
Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Medexus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medexus Pharmaceuticals wasn't on the list.
While Medexus Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
